ArticleThoracic cancer2019

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Keisuke Baba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.